Latest Cancer immunotherapy Stories
Initial Closing is for $10 Million FREDERICK, Md., Aug.
HPV Immune Therapy VGX-3100 to Advance into Phase III PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug.
TAMPA, Fla., Aug.
Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass.
TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome
SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of
GRENOBLE, France, July 8, 2014 /PRNewswire/ -- ImmunID announced today that Dr Miguel Perales, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Stem Cell Transplant Fellowship
Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs.
- Large; stout; burly.